Pyrimidyn-Based Dynamin Inhibitors as Novel Cytotoxic Agents

Five focused libraries of pyrimidine-based dynamin GTPase inhibitors, in total 69 compounds were synthesised, and their dynamin inhibition and broad-spectrum cytotoxicity examined. Dynamin plays a crucial role in mitosis, and as such inhibition of dynamin was expected to broadly correlate with the observed cytotoxicity. The pyrimidines synthesised ranged from mono-substituted to trisubstituted. The highest levels of dynamin inhibition were noted with di- and tri- substituted pyrimidines, especially those with pendent amino alkyl chains. Short chains and simple heterocyclic rings reduced dynamin activity. There were three levels of dynamin activity noted: 1-10, 10-25 and 25-60 mu M. Screening of these compounds in a panel of cancer cell lines: SW480 (colon), HT29 (colon), SMA (spontaneous murine astrocytoma), MCF-7 (breast), BE2-C (glioblastoma), SJ-G2 (neuroblastoma), MIA (pancreas), A2780 (ovarian), A431 (skin), H460 (lung), U87 (glioblastoma) and DU145 (prostate) cell lines reveal a good correlation between the observed dynamin inhibition and the observed cytotoxicity. The most active analogues (31 a,b) developed returned average GI(50) values of 1.0 and 0.78 mu M across the twelve cell lines examined. These active analogues were: N-2-(3-dimethylaminopropyl)-N-4-dodecyl-6-methylpyrimidine-2,4-diamine (31 a) and N-4-(3-dimethylaminopropyl)-N-2-dodecyl-6-methylpyrimidine-2,4-diamine (31 b).

Automated summary

The study involved the synthesis of pyrimidine-based dynamin GTPase inhibitors, with di- and tri-substituted pyrimidines showing higher levels of dynamin inhibition and potentially stronger cytotoxicity. These inhibitors demonstrated a good correlation between dynamin inhibition and cytotoxicity in various cancer cell lines.